在JAK抑制剂患者的皮肤T细胞淋巴瘤:一个病例报告
Sophy Mo1, Dominique Friedmann1
1Department of Medicine, Dermatology Service, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
SAGE open medical case reports
|February 15, 2024
概括
简氏激酶 (JAK) 抑制剂可能会增加恶性瘤的风险. 一个皮肤T细胞淋巴瘤的病例可能与对亚托皮肤炎的JAK抑制剂治疗有关,这突显了需要谨慎和进一步研究的必要性.
科学领域:
- 皮肤病学 皮肤病学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 简氏激酶 (JAK) 抑制剂越来越多地用于皮肤病.
- 美国食品和药物管理局注意到,使用JAK抑制剂可能会增加恶性瘤风险.
相关概念视频
01:20The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
01:27Tumor Immunotherapy
524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524